Symptom information is usually collected using patient-reported outcome (PRO) standardized questionnaires. However, there is a discordance between adverse event (AE) and PRO. Because, the current oncology practice for adverse event is based on the implicit assumption that an accurate portrait of patient’ subjective experiences can be provided by oncologists’ documentation alone. Prostate cancer working group 3 (PCWG3) mentioned the importance of patient-centered drug development and reporting the patient experience on study. Not only clinical trial but also clinical practice, measurement, and collection of PROs are important. Surprising results were presented at ASCO 2017 annual meeting as plenary session. In this study, patients in the PRO study arm were associated with prolonged survival compared with the standard care without these assessments. These results suggested that collecting PROs timely and correctively improves not only QoL but also survival.
